New Haven biotech Arvinas has unveiled five new preclinical programs that aim to treat various types of cancer and a fatal neurological disorder.
Arvinas’s drugs use PROTACs (short for proteolysis-targeting chimeras), a technology developed by Yale scientist and company founder Craig Crews, to remove disease-causing proteins by harnessing the body’s natural cellular trash-disposal mechanism.